# Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

> **NCT01839773** · PHASE3 · COMPLETED · sponsor: **Daehwa Pharmaceutical Co., Ltd.** · enrollment: 238 (actual)

## Conditions studied

- Stage IV Gastric Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01839773
- **Lead sponsor:** Daehwa Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839773, "Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01839773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*